RT Journal Article
SR Electronic
T1 Breast cancer risks associated with missense variants in breast cancer susceptibility genes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.02.21262369
DO 10.1101/2021.09.02.21262369
A1 Dorling, Leila
A1 Carvalho, Sara
A1 Allen, Jamie
A1 Parsons, Michael T.
A1 Fortuno, Cristina
A1 González-Neira, Anna
A1 Heijl, Stephan M.
A1 Adank, Muriel A.
A1 Ahearn, Thomas U.
A1 Andrulis, Irene L.
A1 Auvinen, Päivi
A1 Becher, Heiko
A1 Beckmann, Matthias W.
A1 Behrens, Sabine
A1 Bermisheva, Marina
A1 Bogdanova, Natalia V.
A1 Bojesen, Stig E.
A1 Bolla, Manjeet K.
A1 Bremer, Michael
A1 Briceno, Ignacio
A1 Camp, Nicola J.
A1 Campbell, Archie
A1 Castelao, Jose E.
A1 Chang-Claude, Jenny
A1 Chanock, Stephen J.
A1 Chenevix-Trench, Georgia
A1 ,
A1 Collée, J. Margriet
A1 Czene, Kamila
A1 Dennis, Joe
A1 Dörk, Thilo
A1 Eriksson, Mikael
A1 Evans, D. Gareth
A1 Fasching, Peter A.
A1 Figueroa, Jonine
A1 Flyger, Henrik
A1 Gabrielson, Marike
A1 Gago-Dominguez, Manuela
A1 García-Closas, Montserrat
A1 Giles, Graham G.
A1 Glendon, Gord
A1 Guénel, Pascal
A1 Gündert, Melanie
A1 Hadjisavvas, Andreas
A1 Hahnen, Eric
A1 Hall, Per
A1 Hamann, Ute
A1 Harkness, Elaine F.
A1 Hartman, Mikael
A1 Hogervorst, Frans B.L.
A1 Hollestelle, Antoinette
A1 Hoppe, Reiner
A1 Howell, Anthony
A1 ,
A1 ,
A1 Jakubowska, Anna
A1 Jung, Audrey
A1 Khusnutdinova, Elza
A1 Kim, Sung-Won
A1 Ko, Yon-Dschun
A1 Kristensen, Vessela N.
A1 Lakeman, Inge M.M.
A1 Li, Jingmei
A1 Lindblom, Annika
A1 Loizidou, Maria A.
A1 Lophatananon, Artitaya
A1 Lubiński, Jan
A1 Luccarini, Craig
A1 Madsen, Michael J.
A1 Mannermaa, Arto
A1 Manoochehri, Mehdi
A1 Margolin, Sara
A1 Mavroudis, Dimitrios
A1 Milne, Roger L.
A1 Mohd Taib, Nur Aishah
A1 Muir, Kenneth
A1 Nevanlinna, Heli
A1 Newman, William G.
A1 Oosterwijk, Jan C.
A1 Park, Sue K.
A1 Peterlongo, Paolo
A1 Radice, Paolo
A1 Saloustros, Emmanouil
A1 Sawyer, Elinor J.
A1 Schmutzler, Rita K.
A1 Shah, Mitul
A1 Sim, Xueling
A1 Southey, Melissa C.
A1 Surowy, Harald
A1 Suvanto, Maija
A1 Tomlinson, Ian
A1 Torres, Diana
A1 Truong, Thérèse
A1 van Asperen, Christi J.
A1 Waltes, Regina
A1 Wang, Qin
A1 Yang, Xiaohong R.
A1 Pharoah, Paul D.P.
A1 Schmidt, Marjanka K.
A1 Benitez, Javier
A1 Vroling, Bas
A1 Dunning, Alison M.
A1 Teo, Soo Hwang
A1 Kvist, Anders
A1 de la Hoya, Miguel
A1 Devilee, Peter
A1 Spurdle, Amanda B.
A1 Vreeswijk, Maaike P.G.
A1 Easton, Douglas F.
YR 2021
UL http://medrxiv.org/content/early/2021/09/15/2021.09.02.21262369.abstract
AB BACKGROUND Protein truncating variants in ATM, BRCA1, BRCA2, CHEK2 and PALB2 are associated with increased breast cancer risk, but risks associated with missense variants in these genes are uncertain.METHODS Combining 59,639 breast cancer cases and 53,165 controls, we sampled training (80%) and validation (20%) sets to analyze rare missense variants in ATM (1,146 training variants), BRCA1 (644), BRCA2 (1,425), CHEK2 (325) and PALB2 (472). We evaluated breast cancer risks according to five in-silico prediction-of-deleteriousness algorithms, functional protein domain, and frequency, using logistic regression models and also mixture models in which a subset of variants was assumed to be risk-associated.RESULTS The most predictive in-silico algorithms were Helix (BRCA1, BRCA2 and CHEK2) and CADD (ATM). Increased risks appeared restricted to functional protein domains for ATM (FAT and PIK domains) and BRCA1 (RING and BRCT domains). For ATM, BRCA1 and BRCA2, data were compatible with small subsets (approximately 7%, 2% and 0.6%, respectively) of rare missense variants giving similar risk to those of protein truncating variants in the same gene. For CHEK2, data were more consistent with a large fraction (approximately 60%) of rare missense variants giving a lower risk (OR 1.75, 95% CI (1.47-2.08)) than CHEK2 protein truncating variants. There was little evidence for an association with risk for missense variants in PALB2. The best fitting models were well calibrated in the validation set.CONCLUSIONS These results will inform risk prediction models and the selection of candidate variants for functional assays, and could contribute to the clinical reporting of gene panel testing for breast cancer susceptibility.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe sequencing and analysis for this project was funded by the European Union's Horizon 2020 Research and Innovation Programme (BRIDGES: grant number 634935) and the Wellcome Trust [grant no: v203477/Z/16/Z]. BCAC co-ordination was additionally funded by the European Union's Horizon 2020 Research and Innovation Programme (BRIDGES: grant number 634935, BCAST: grant number 633784) and by Cancer Research UK [C1287/A16563]. Study specific funding is given in the Supplemental Note. No authors received payment or services from a third party for any aspect of the submitted work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval to use the BCAC data included in this study was given by the Data Access Co-ordinating Committee (concept #672). All contributing BCAC studies were approved by the relevant ethical review boards, details of which can be found in Additional Table 14.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSummary level genotype data are available via http://bcac.ccge.medschl.cam.ac.uk and in Supplementary Tables 9-13. Individual level data are available via the BCAC Data Access Co-ordinating Committee (bcac@medschl.cam.ac.uk)PTVsProtein truncating variantsVUSVariants of uncertain significanceBCACBreast Cancer Association ConsortiumVEPEnsembl Variant Effect PredictorCADDCombined Annotation Dependent DepletionREVELRare Exome Variant Ensembl LearnerSGESaturation Genome EditingLRLogistic regressionOROdds ratioEMExpectation-maximizationPPPosterior probabilityQ5Fifth quntileLOFSGELoss of functionFUNCSGEFunctionalINTSGEIntermediate functionGWASGenome wide association study